2cd phase 3 trialMy thoughts are for an Endo news release stating that the trial has started. Up til now I have been concerned that Endo might have bought the rights to Urocidin to protect their own drugs for bladder cancer. $ 25 mil is pretty cheap to stall competition. I have vowed to not purchase another share until Endo starts their phase 3 B trial. They have had time to bring their teams up to speed and arrange sites for these trials. If this is what is behind the bump today and a release follows, I would think we will see the green side of a buck shortly. Endo,s endorsing urocidin will bring in more investors from the states and our fund managers will finally wake up and play catch up. I will also be adding. If the pop is regarding EcoNiche we had a capacity to produce 60,000 doses per month. I don't know if that lab is still up to scale production wise or if it was canibalized for the new expansion. Sales will not be easy though without some external prodding and assistance.
Well I won,t get too excited til I see a release. We have been down that road too many times, but I'm betting on the trial starting. Luck to all, lets see what tomorrow brings....Dusty